Patent: 10,335,486
✉ Email this page to a colleague
Summary for Patent: 10,335,486
| Title: | MRNA combination therapy for the treatment of cancer |
| Abstract: | The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally. |
| Inventor(s): | Frederick; Joshua P. (Boston, MA), Hewitt; Susannah (Jamaica Plain, MA), Bai; Ailin (Newton, MA), Hoge; Stephen G. (Brookline, MA), Presnyak; Vladimir (Cambridge, MA), McFadyen; Iain (Arlington, MA), Benenato; Kerry (Sudbury, MA), Kumarasinghe; Ellalahewage Sathyajith (Harvard, MA) |
| Assignee: | ModernaTX, Inc. (Cambridge, MA) |
| Application Number: | 15/996,146 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,335,486
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2036-05-18 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2036-05-18 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2036-05-18 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2036-05-18 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2036-05-18 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2036-05-18 |
| Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2036-05-18 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
